Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitorsMaud Marques(IGNIS Innovation (Canada)), Michael Witcher(McGill University)BMC MedicineSeptember 9, 201510.1186/s12916-015-0454-9Cited by 19SaveCiteExport RISWatch citationsRelated PapersGlioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles|Blood Advances|2021|79STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer|Nature Communications|2021|61